propranolol Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
beta-adrenoreceptor antagonists 2303 525-66-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • propranolol
  • betalong
  • DL-Propranolol
  • racemic propranolol
  • beta-Propranolol
  • propranolol hydrochloride
  • hemangiol
  • propranolol HCl
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
  • Molecular weight: 259.35
  • Formula: C16H21NO2
  • CLOGP: 2.75
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 41.49
  • ALOGS: -3.51
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.16 g O
0.16 g P

Approvals:

DateAgencyCompanyOrphan
Nov. 13, 1967 FDA BAXTER HLTHCARE CORP

FDA Adverse Event Reporting System

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 2044.99 37.13 542 3106 30572 3351639
Toxicity to various agents 1336.88 37.13 429 3219 46625 3335586
Bradycardia 1068.86 37.13 287 3361 16382 3365829
Cardiac arrest 984.37 37.13 300 3348 27019 3355192
Hypotension 945.24 37.13 336 3312 49178 3333033
Overdose 779.01 37.13 265 3383 33713 3348498
Cardio-respiratory arrest 521.17 37.13 162 3486 15278 3366933
Intentional overdose 514.95 37.13 160 3488 15065 3367146
Respiratory arrest 494.08 37.13 145 3503 11223 3370988
Hypoglycaemia 448.56 37.13 142 3506 14176 3368035
Cardiogenic shock 324.92 37.13 83 3565 3783 3378428
Drug interaction 300.34 37.13 147 3501 46665 3335546
Circulatory collapse 279.19 37.13 81 3567 5968 3376243
Off label use 249.38 37.13 136 3512 53841 3328370
Sinus bradycardia 237.64 37.13 63 3585 3316 3378895
Drug administered to patient of inappropriate age 237.47 37.13 52 3596 1200 3381011
Heart rate decreased 227.27 37.13 67 3581 5211 3377000
Seizure 220.89 37.13 114 3534 40286 3341925
Poisoning 203.14 37.13 61 3587 5051 3377160
Peripheral coldness 200.15 37.13 51 3597 2291 3379920
Unresponsive to stimuli 180.11 37.13 62 3586 7946 3374265
Depressed level of consciousness 169.08 37.13 65 3583 11400 3370811
Blood pressure decreased 167.48 37.13 68 3580 13768 3368443
Coma 166.86 37.13 66 3582 12486 3369725
Pulseless electrical activity 166.27 37.13 41 3607 1607 3380604
Hypoglycaemic seizure 155.49 37.13 28 3620 222 3381989
Drug hypersensitivity 153.60 37.13 86 3562 35594 3346617
Death 150.60 37.13 151 3497 152173 3230038
Suicide attempt 148.73 37.13 65 3583 15782 3366429
Electrocardiogram QRS complex prolonged 148.56 37.13 36 3612 1310 3380901
Somnolence 136.86 37.13 77 3571 32127 3350084
Loss of consciousness 135.28 37.13 73 3575 28074 3354137
Shock 134.07 37.13 48 3600 6889 3375322
Hyperkalaemia 124.69 37.13 52 3596 11242 3370969
Premature baby 124.56 37.13 46 3602 7207 3375004
Cyanosis 121.41 37.13 41 3607 4945 3377266
Electrocardiogram QT prolonged 116.80 37.13 49 3599 10746 3371465
Intentional product misuse 115.56 37.13 51 3597 12650 3369561
Exposure via ingestion 115.25 37.13 30 3618 1463 3380748
Hyperhidrosis 112.73 37.13 61 3587 23549 3358662
Metabolic acidosis 112.54 37.13 45 3603 8733 3373478
Lethargy 110.75 37.13 51 3597 13964 3368247
Bronchial hyperreactivity 108.97 37.13 22 3626 336 3381875
Drug ineffective 108.71 37.13 112 3536 115978 3266233
Myopathy 108.69 37.13 33 3615 2826 3379385
Exposure during pregnancy 101.28 37.13 60 3588 27503 3354708
Poisoning deliberate 100.69 37.13 25 3623 1006 3381205
Dyspnoea 97.53 37.13 100 3548 102834 3279377
Multiple organ dysfunction syndrome 97.13 37.13 47 3601 14363 3367848
Hypothermia 96.60 37.13 31 3617 3184 3379027
Vomiting 94.01 37.13 92 3556 89439 3292772
Maternal drugs affecting foetus 91.75 37.13 31 3617 3740 3378471
Insomnia 89.11 37.13 61 3587 35837 3346374
Dizziness 88.56 37.13 83 3565 76429 3305782
Poor quality sleep 87.93 37.13 27 3621 2400 3379811
Palpitations 87.42 37.13 48 3600 19035 3363176
Tachycardia 86.15 37.13 51 3597 23320 3358891
Syncope 84.34 37.13 52 3596 25581 3356630
Condition aggravated 84.22 37.13 61 3587 39172 3343039
Encapsulating peritoneal sclerosis 83.53 37.13 16 3632 183 3382028
Hypertension 83.01 37.13 60 3588 38406 3343805
Phaeochromocytoma 81.78 37.13 16 3632 206 3382005
Medication error 80.83 37.13 39 3609 11832 3370379
Supraventricular tachycardia 80.12 37.13 27 3621 3229 3378982
Respiratory depression 79.61 37.13 28 3620 3806 3378405
Mydriasis 78.85 37.13 26 3622 2908 3379303
Torsade de pointes 78.03 37.13 26 3622 3003 3379208
Atrioventricular block 73.85 37.13 23 3625 2141 3380070
Foetal exposure during pregnancy 73.65 37.13 40 3608 15511 3366700
Tremor 72.60 37.13 49 3599 28095 3354116
Agitation 72.59 37.13 43 3605 19663 3362548
Brain injury 72.23 37.13 21 3627 1546 3380665
Hypotonia 71.40 37.13 24 3624 2847 3379364
Ventricular tachycardia 68.05 37.13 28 3620 5834 3376377
Restlessness 68.03 37.13 30 3618 7408 3374803
Atrioventricular block complete 67.15 37.13 22 3626 2410 3379801
Accidental overdose 66.03 37.13 29 3619 7089 3375122
Sleep disorder 64.83 37.13 30 3618 8283 3373928
Foetal growth restriction 64.35 37.13 20 3628 1849 3380362
Hyperthyroidism 63.85 37.13 22 3626 2812 3379399
Pulmonary oedema 63.04 37.13 33 3615 11878 3370333
Cholestasis of pregnancy 61.90 37.13 11 3637 80 3382131
Aggression 61.56 37.13 32 3616 11353 3370858
Akathisia 61.27 37.13 21 3627 2642 3379569
Brugada syndrome 60.88 37.13 13 3635 264 3381947
Thyrotoxic crisis 60.26 37.13 12 3636 170 3382041
Pneumonia aspiration 59.73 37.13 27 3621 7061 3375150
Rhabdomyolysis 59.69 37.13 35 3613 15694 3366517
Acute kidney injury 57.55 37.13 54 3594 49629 3332582
Fall 57.00 37.13 58 3590 58825 3323386
Malaise 53.84 37.13 59 3589 65118 3317093
Product quality issue 53.76 37.13 40 3608 26695 3355516
Disorientation 53.54 37.13 28 3620 10051 3372160
Blood glucose increased 53.34 37.13 35 3613 19120 3363091
Confusional state 53.26 37.13 46 3602 37952 3344259
Blood pressure increased 53.26 37.13 37 3611 22193 3360018
Nausea 53.17 37.13 83 3565 129562 3252649
Ventricular arrhythmia 52.12 37.13 15 3633 1064 3381147
Pallor 51.55 37.13 23 3625 5832 3376379
Caesarean section 50.43 37.13 21 3627 4505 3377706
Haemangioma 50.09 37.13 13 3635 625 3381586
Wheezing 50.08 37.13 25 3623 8146 3374065
Nightmare 48.93 37.13 22 3626 5680 3376531
Suicidal ideation 48.44 37.13 32 3616 17673 3364538
Foetal alcohol syndrome 47.92 37.13 8 3640 38 3382173
Apnoea 47.11 37.13 17 3631 2485 3379726
Eosinophilic myocarditis 47.02 37.13 10 3638 199 3382012
Respiratory distress 46.55 37.13 24 3624 8364 3373847
Cardiotoxicity 45.04 37.13 15 3633 1727 3380484
Ventricular fibrillation 44.58 37.13 19 3629 4314 3377897
Anxiety 43.81 37.13 42 3606 39587 3342624
Pupil fixed 43.65 37.13 12 3636 720 3381491
Asthenia 43.39 37.13 53 3595 65612 3316599
Foetal death 42.97 37.13 15 3633 1991 3380220
Raynaud's phenomenon 42.48 37.13 13 3635 1140 3381071
Sinus tachycardia 42.39 37.13 19 3629 4866 3377345
Acute respiratory distress syndrome 42.02 37.13 20 3628 5874 3376337
Hyperreflexia 41.82 37.13 13 3635 1201 3381010
Product use issue 41.55 37.13 28 3620 15973 3366238
Therapeutic response unexpected 41.37 37.13 19 3629 5149 3377062
Drug administration error 40.82 37.13 20 3628 6256 3375955
Nodal rhythm 40.75 37.13 11 3637 616 3381595
Diarrhoea 40.21 37.13 65 3583 104283 3277928
Toxic leukoencephalopathy 40.14 37.13 7 3641 45 3382166
Irritability 40.03 37.13 24 3624 11192 3371019
Bezoar 39.04 37.13 9 3639 262 3381949
Hepatic encephalopathy 38.73 37.13 16 3632 3361 3378850
Orthostatic hypotension 38.70 37.13 18 3630 5018 3377193
Respiratory failure 38.59 37.13 31 3617 23110 3359101
Miosis 38.56 37.13 14 3634 2082 3380129
Dysmorphism 38.25 37.13 11 3637 778 3381433
Drug abuse 38.11 37.13 28 3620 18302 3363909

Pharmacologic Action:

SourceCodeDescription
ATC C07AA05 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS
Beta blocking agents, non-selective
ATC C07BA05 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS AND THIAZIDES
Beta blocking agents, non-selective, and thiazides
ATC C07FX01 CARDIOVASCULAR SYSTEM
BETA BLOCKING AGENTS
BETA BLOCKING AGENTS, OTHER COMBINATIONS
Beta blocking agents, other combinations
FDA EPC N0000175556 beta-Adrenergic Blocker
MeSH PA D018663 Adrenergic Agents
MeSH PA D018674 Adrenergic Antagonists
MeSH PA D000319 Adrenergic beta-Antagonists
MeSH PA D000889 Anti-Arrhythmia Agents
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35530 beta-adrenergic antagonist
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:38070 anti-arrhythmia drug
CHEBI has role CHEBI:35620 vasodilator agent
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Supraventricular tachycardia indication 6456007
Hypertensive disorder indication 38341003 DOID:10763
Atrial fibrillation indication 49436004 DOID:0060224
Angina pectoris indication 194828000
Hypertrophic cardiomyopathy indication 233873004 DOID:11984
Idiopathic hypertrophic subaortic stenosis indication 360465008
Hemangioma indication 400210000 DOID:255
Essential tremor indication 609558009 DOID:4990
Arrhythmias During Surgery indication
Migraine Prevention indication
Life-Threatening Ventricular Tachycardia indication
Myocardial Reinfarction Prevention indication
Pheochromocytoma Adjunct Therapy indication
Thyrotoxicosis off-label use 90739004 DOID:7997
Mitral valve prolapse off-label use 409712001 DOID:988
Prevention of Congenital Long QT Syndrome associated Ventricular Arrhythmia off-label use
Prevention of Post Cardio-Thoracic Surgery Atrial Fibrillation off-label use
Prevention of Bleeding Esophageal Varices off-label use
Anuria contraindication 2472002 DOID:2983
Bronchospasm contraindication 4386001
Hypercholesterolemia contraindication 13644009
Secondary angle-closure glaucoma contraindication 21571006
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Depressive disorder contraindication 35489007 DOID:2848
Hyperuricemia contraindication 35885006 DOID:1920
Sick sinus syndrome contraindication 36083008 DOID:13884
Hypokalemia contraindication 43339004
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Chronic bronchitis contraindication 63480004 DOID:6132
Hypercalcemia contraindication 66931009 DOID:12678
Hyperparathyroidism contraindication 66999008 DOID:13543
Hypochloremic alkalosis contraindication 70134007
Hepatic coma contraindication 72836002 DOID:12550
Diabetes mellitus contraindication 73211009 DOID:9351
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Pulmonary emphysema contraindication 87433001
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:2527
Myasthenia gravis contraindication 91637004 DOID:437
Disorder of muscle contraindication 129565002 DOID:423
Hypomagnesemia contraindication 190855004
Second degree atrioventricular block contraindication 195042002
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007 DOID:9993
Raynaud's phenomenon contraindication 266261006
Neonatal hyperbilirubinemia contraindication 281610001
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Azotemia contraindication 445009001
Smokes tobacco daily contraindication 449868002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.19 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
4.28MG/ML HEMANGEOL PIERRE FABRE DERMA N205410 March 14, 2014 RX SOLUTION ORAL 8338489 Oct. 16, 2028 METHOD TO TREAT HEMANGIOMA.

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
4.28MG/ML HEMANGEOL PIERRE FABRE DERMA N205410 March 14, 2014 RX SOLUTION ORAL March 14, 2021 TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR ANTAGONIST Ki 8.25 WOMBAT-PK DRUG LABEL
Beta-1 adrenergic receptor GPCR ANTAGONIST Ki 8.71 WOMBAT-PK DRUG LABEL
5-hydroxytryptamine receptor 1B GPCR Ki 6.20 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.35 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 6.91 PDSP
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 5.92 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.69 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.66 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 5.92 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.85 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 5.70 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.40 DRUG MATRIX
Multidrug resistance protein 1 Transporter Ki 4.32 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.20 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel IC50 4.30 WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1C Ion channel Ki 4.32 WOMBAT-PK
Beta-3 adrenergic receptor GPCR ANTAGONIST Ki 6.22 WOMBAT-PK
Histamine H1 receptor GPCR Ki 4.70 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 5.38 PDSP
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.67 DRUG MATRIX
Beta-2 adrenergic receptor GPCR Kd 9.05 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.30 CHEMBL
Beta-2 adrenergic receptor GPCR IC50 7.77 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 7.05 CHEMBL
D(2) dopamine receptor GPCR Ki 4.89 CHEMBL
Adrenergic receptor beta GPCR Ki 8.62 CHEMBL
Beta-1 adrenergic receptor GPCR Ki 8.52 CHEMBL
Beta-2 adrenergic receptor GPCR Kd 9.01 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 8.76 CHEMBL
Beta-3 adrenergic receptor Unclassified ANTAGONIST Ki 6.60 IUPHAR

External reference:

IDSource
DB00571 DRUGBANK_ID
564 IUPHAR_LIGAND_ID
4019916 VUID
N0000148001 NUI
C0033497 UMLSCUI
D00483 KEGG_DRUG
CHEMBL27 ChEMBL_ID
4946 PUBCHEM_CID
4019916 VANDF
8787 RXNORM
372772003 SNOMEDCT_US
55745002 SNOMEDCT_US
d00032 MMSL
N0000006760 NDFRT
N0000148001 NDFRT
004740 NDDF
9Y8NXQ24VQ UNII
1940 INN_ID
CHEBI:8499 CHEBI
CHEMBL1671 ChEMBL_ID
D011433 MESH_DESCRIPTOR_UI
318-98-9 SECONDARY_CAS_RN
SNP PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3727 SOLUTION 20 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3730 SOLUTION 40 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1659 TABLET 10 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1660 TABLET 20 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1661 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1662 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-1693 TABLET 60 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9872 INJECTION 1 mg INTRAVENOUS ANDA 13 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2778 CAPSULE, EXTENDED RELEASE 60 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2779 CAPSULE, EXTENDED RELEASE 80 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2780 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2781 CAPSULE, EXTENDED RELEASE 160 mg ORAL ANDA 12 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0084 CAPSULE, EXTENDED RELEASE 60 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0085 CAPSULE, EXTENDED RELEASE 80 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0086 CAPSULE, EXTENDED RELEASE 120 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0245-0087 CAPSULE, EXTENDED RELEASE 160 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0182 TABLET 10 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0183 TABLET 20 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0184 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0185 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0187 TABLET 60 mg ORAL ANDA 11 sections
Propranolol Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-0347 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride and Hydrochlorothiazide HUMAN PRESCRIPTION DRUG LABEL 2 0378-0731 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5554 TABLET 10 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5555 TABLET 20 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5556 TABLET 40 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-5557 TABLET 80 mg ORAL ANDA 11 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5482 TABLET 10 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5483 TABLET 20 mg ORAL ANDA 14 sections
Propranolol Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-5484 TABLET 40 mg ORAL ANDA 14 sections